Naokata Sumitomo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Naokata Sumitomo has a total of 363 co-authors. Here are the top co-authors by number of shared publications:
Toshiki Kobayashi
Saitama Medical University International Medical Center, Hidaka, Japan
24 shared publicationsShigeki Yoshiba
Saitama Medical University International Medical Center, Hidaka, Japan
19 shared publicationsTakuro Kojima
Department of Pediatric Cardiology Saitama Medical University International Medical Center Saitama Japan
19 shared publicationsShota Muraji
Department of Pediatric Cardiology, Saitama Medical University International Medical Center , Hidaka
18 shared publicationsHitoshi Mori
Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Hidaka, Japan
11 shared publications- Hitoshi Mori
Department of Cardiology Saitama Medical University International Medical Center Hidaka Saitama Japan
10 shared publications
Latest Publications
- Open Access
- 13 July 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4)
Midterm Efficacy of SubcutAneous Implantable CardioVErter ‐Defibrillator in ≤ 18 Year‐Old CHILDREN ( SAVE CHILDREN ‐ II Registry)
Background: The subcutaneous implantable cardioverter‐defibrillator (S‐ICD) avoids transvenous leads and is a promising option for sudden cardiac death (SCD) prevention in pediatric patients. However, mid‐term outcomes and post‐shock management strategies remain insufficiently characterized. Methods: This multicenter, retrospective observational study included pediatric patients (≤ 18 years) who underwent S‐ICD implantation between February 2016 and July 2021. Clinical characteristics, pre‐implant screening, procedural details, device‐related events, and follow‐up data were analyzed. The incidence and management of appropriate and inappropriate therapies and subsequent recurrence were evaluated. Results: Ninety‐six patients (median age 14.5 years) were enrolled and followed for a median of 70 months (29–75.0 months). Sensing vector suitability remained stable despite somatic growth. Appropriate shocks occurred in 32 patients (33.7%), while inappropriate shocks occurred in 27 (28.4%). After appropriate therapy, intensified pharmacological treatment and catheter ablation prevented recurrent device therapy in 45.5% and 50.0% of cases, respectively, although device shock occurred in 50.9% despite intervention. Following inappropriate therapy, device reprogramming and lifestyle guidance prevented recurrence in 71.4% of patients (15/21). Device‐related infection was rare (2 cases), and no lead fractures were observed. Conclusions: S‐ICD therapy demonstrated favorable mid‐term safety and efficacy in pediatric patients, with durable sensing performance and a low incidence of device‐related infection. Although inappropriate shocks were not uncommon, appropriate post‐shock management effectively reduced recurrence, supporting S‐ICD as a viable option for selected pediatric patients without pacing requirements.
- 13 July 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4)
Open AccessMidterm Efficacy of SubcutAneous Implantable CardioVErter ‐Defibrillator in ≤ 18 Year‐Old CHILDREN ( SAVE CHILDREN ‐ II Registry)
Background: The subcutaneous implantable cardioverter‐defibrillator (S‐ICD) avoids transvenous leads and is a promising option for sudden cardiac death (SCD) prevention in pediatric patients. However, mid‐term outcomes and post‐shock management strategies remain insufficiently characterized. Methods: This multicenter, retrospective observational study included pediatric patients (≤ 18 years) who underwent S‐ICD implantation between February 2016 and July 2021. Clinical characteristics, pre‐implant screening, procedural details, device‐related events, and follow‐up data were analyzed. The incidence and management of appropriate and inappropriate therapies and subsequent recurrence were evaluated. Results: Ninety‐six patients (median age 14.5 years) were enrolled and followed for a median of 70 months (29–75.0 months). Sensing vector suitability remained stable despite somatic growth. Appropriate shocks occurred in 32 patients (33.7%), while inappropriate shocks occurred in 27 (28.4%). After appropriate therapy, intensified pharmacological treatment and catheter ablation prevented recurrent device therapy in 45.5% and 50.0% of cases, respectively, although device shock occurred in 50.9% despite intervention. Following inappropriate therapy, device reprogramming and lifestyle guidance prevented recurrence in 71.4% of patients (15/21). Device‐related infection was rare (2 cases), and no lead fractures were observed. Conclusions: S‐ICD therapy demonstrated favorable mid‐term safety and efficacy in pediatric patients, with durable sensing performance and a low incidence of device‐related infection. Although inappropriate shocks were not uncommon, appropriate post‐shock management effectively reduced recurrence, supporting S‐ICD as a viable option for selected pediatric patients without pacing requirements.
- Open Access
- 25 June 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (3) , e70383
Current Topics of Progressive Cardiac Conduction Disease
Progressive cardiac conduction disease (PCCD) is a rare inheritable cardiac conduction system disease that may lead to complete heart block, syncope, or sudden cardiac death. The estimated incidence of PCCD is 0.0005%/year. Recent advances in genetics have revealed a wide variety of diseases associated with the development of PCCD. Ion channel genes ( SCN5A, KCNK17, TRPM4, HCN4 ), gap junction genes ( GJA5 , GJC1 ), genes associated with myopathy ( LMNA , EMD , DES , DMD , TNNI3K , DMPK, ZNF9 ), transcription factor genes ( NKX2‐5 , TBX5 ), genes associated with metabolic disease ( PRKAG2 , LAMP2 , GLA ), and mitochondrial gene variants have all been associated with the occurrence of PCCD. Pacemaker implantation is the first‐line therapy for PCCD, but implantable cardioverter defibrillator implantation should be considered in some cases. This review aims to provide a clinically relevant overview of these different forms, with emphasis on their genetic basis and phenotypic expression. We propose a practical classification distinguishing isolated and associated forms of PCCD and discuss the implications for diagnosis, risk stratification, and patient management.
- 25 June 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (3) , e70383
Open AccessCurrent Topics of Progressive Cardiac Conduction Disease
Progressive cardiac conduction disease (PCCD) is a rare inheritable cardiac conduction system disease that may lead to complete heart block, syncope, or sudden cardiac death. The estimated incidence of PCCD is 0.0005%/year. Recent advances in genetics have revealed a wide variety of diseases associated with the development of PCCD. Ion channel genes ( SCN5A, KCNK17, TRPM4, HCN4 ), gap junction genes ( GJA5 , GJC1 ), genes associated with myopathy ( LMNA , EMD , DES , DMD , TNNI3K , DMPK, ZNF9 ), transcription factor genes ( NKX2‐5 , TBX5 ), genes associated with metabolic disease ( PRKAG2 , LAMP2 , GLA ), and mitochondrial gene variants have all been associated with the occurrence of PCCD. Pacemaker implantation is the first‐line therapy for PCCD, but implantable cardioverter defibrillator implantation should be considered in some cases. This review aims to provide a clinically relevant overview of these different forms, with emphasis on their genetic basis and phenotypic expression. We propose a practical classification distinguishing isolated and associated forms of PCCD and discuss the implications for diagnosis, risk stratification, and patient management.
- Open Access
- 20 April 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (2)
REgistry Of Catheter AbLation After Congenital Heart Disease Surgery( REAL ‐ CHD Registry)
Background: Advances in surgical management have improved long‐term survival in patients with congenital heart disease (CHD), leading to a growing population of adults with postoperative arrhythmias. However, contemporary data on catheter ablation practice and outcomes in patients with CHD remain limited. Methods: This multicenter, retrospective registry study included patients who underwent catheter ablation for postoperative CHD‐related arrhythmias between April 2007 and December 2025 at 10 centers. CHD severity was classified as mild, moderate, or severe according to Japanese Circulation Society guidelines. Procedural characteristics, arrhythmia profiles, acute procedural outcomes, and complications were analyzed. Associations between age, disease severity, arrhythmia burden, and procedural success were evaluated using regression analyses. Results: A total of 1 719 patients were included. The number of ablation procedures increased over time across all CHD severity categories. Increasing age was associated with lower disease severity, whereas patients with severe CHD, particularly those after a Fontan repair, underwent ablation at younger ages. Procedural success decreased with increasing CHD severity (complete success: 92.5% in mild, 81.4% in moderate, and 71.4% in severe CHD) and with a greater number of induced arrhythmia types. Overall, procedure‐related complications occurred in 2.3% of patients, with worsening heart failure being the most frequent non‐vascular adverse event. Conclusion: In a large contemporary Japanese cohort, catheter ablation for postoperative CHD‐related arrhythmias was increasingly performed and demonstrated acceptable safety. However, procedural success was lower in patients with more severe CHD and greater arrhythmia complexity, highlighting the need for specialized ablation strategies and careful periprocedural management in this growing population.
- 20 April 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (2)
Open AccessREgistry Of Catheter AbLation After Congenital Heart Disease Surgery( REAL ‐ CHD Registry)
Background: Advances in surgical management have improved long‐term survival in patients with congenital heart disease (CHD), leading to a growing population of adults with postoperative arrhythmias. However, contemporary data on catheter ablation practice and outcomes in patients with CHD remain limited. Methods: This multicenter, retrospective registry study included patients who underwent catheter ablation for postoperative CHD‐related arrhythmias between April 2007 and December 2025 at 10 centers. CHD severity was classified as mild, moderate, or severe according to Japanese Circulation Society guidelines. Procedural characteristics, arrhythmia profiles, acute procedural outcomes, and complications were analyzed. Associations between age, disease severity, arrhythmia burden, and procedural success were evaluated using regression analyses. Results: A total of 1 719 patients were included. The number of ablation procedures increased over time across all CHD severity categories. Increasing age was associated with lower disease severity, whereas patients with severe CHD, particularly those after a Fontan repair, underwent ablation at younger ages. Procedural success decreased with increasing CHD severity (complete success: 92.5% in mild, 81.4% in moderate, and 71.4% in severe CHD) and with a greater number of induced arrhythmia types. Overall, procedure‐related complications occurred in 2.3% of patients, with worsening heart failure being the most frequent non‐vascular adverse event. Conclusion: In a large contemporary Japanese cohort, catheter ablation for postoperative CHD‐related arrhythmias was increasingly performed and demonstrated acceptable safety. However, procedural success was lower in patients with more severe CHD and greater arrhythmia complexity, highlighting the need for specialized ablation strategies and careful periprocedural management in this growing population.
- 19 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (33) , 4606-4617
Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification
Background and Aims: Patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) are at risk for potentially life-threatening arrhythmic events (AEs) even while treated with β-blockers. The aim was to develop a model for individualized prediction of AEs in patients with RYR2-mediated CPVT on β-blocker monotherapy. Methods: The derivation and independent validation cohorts included 743 and 129 patients, respectively. AEs were defined as arrhythmic syncope, appropriate implantable cardioverter–defibrillator shock, sudden cardiac arrest (SCA), and sudden cardiac death. Near-fatal or fatal AEs (nf/fAEs) included all AEs except for arrhythmic syncope. Prediction models using Cox regression were developed and internally and externally validated. Results: A total of 102 (13.7%) patients in the derivation cohort and 24 (18.6%) patients in the validation cohort experienced ≥1 AE over a median follow-up of 5.1 [interquartile range (IQR), 7.7] and 2.4 (IQR, 4.4) years, respectively. Predictors of AE were arrhythmic syncope or SCA prior to diagnosis and age at β-blocker initiation. In the derivation and validation cohorts, the optimism-corrected C-indices of the models for AE were 0.67 [95% confidence interval (CI) 0.62–0.72] and 0.59 (95% CI 0.48–0.71), respectively. For nf/fAEs, ventricular arrhythmia severity before β-blocker initiation was a fourth independent predictor, and C-indices of the models in the derivation and validation cohorts were 0.74 (95% CI 0.68–0.80) and 0.60 (95% CI 0.47–0.72), respectively. In the derivation cohort, calibration slopes were 1.00 (95% CI 0.59–1.41) for AE and 1.00 (95% CI 0.69–1.32) for nf/fAE. Conclusions: These externally validated risk prediction models using clinical parameters accurately distinguished CPVT patients on β-blocker monotherapy at low and high risk for future AEs while treated with β-blockers. These models provide guidance for implementation of clinical management therapies to prevent AEs in patients with CPVT.
- 19 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (33) , 4606-4617
Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification
Background and Aims: Patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) are at risk for potentially life-threatening arrhythmic events (AEs) even while treated with β-blockers. The aim was to develop a model for individualized prediction of AEs in patients with RYR2-mediated CPVT on β-blocker monotherapy. Methods: The derivation and independent validation cohorts included 743 and 129 patients, respectively. AEs were defined as arrhythmic syncope, appropriate implantable cardioverter–defibrillator shock, sudden cardiac arrest (SCA), and sudden cardiac death. Near-fatal or fatal AEs (nf/fAEs) included all AEs except for arrhythmic syncope. Prediction models using Cox regression were developed and internally and externally validated. Results: A total of 102 (13.7%) patients in the derivation cohort and 24 (18.6%) patients in the validation cohort experienced ≥1 AE over a median follow-up of 5.1 [interquartile range (IQR), 7.7] and 2.4 (IQR, 4.4) years, respectively. Predictors of AE were arrhythmic syncope or SCA prior to diagnosis and age at β-blocker initiation. In the derivation and validation cohorts, the optimism-corrected C-indices of the models for AE were 0.67 [95% confidence interval (CI) 0.62–0.72] and 0.59 (95% CI 0.48–0.71), respectively. For nf/fAEs, ventricular arrhythmia severity before β-blocker initiation was a fourth independent predictor, and C-indices of the models in the derivation and validation cohorts were 0.74 (95% CI 0.68–0.80) and 0.60 (95% CI 0.47–0.72), respectively. In the derivation cohort, calibration slopes were 1.00 (95% CI 0.59–1.41) for AE and 1.00 (95% CI 0.69–1.32) for nf/fAE. Conclusions: These externally validated risk prediction models using clinical parameters accurately distinguished CPVT patients on β-blocker monotherapy at low and high risk for future AEs while treated with β-blockers. These models provide guidance for implementation of clinical management therapies to prevent AEs in patients with CPVT.
- 5 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (13) , 1263-1266
Sex-specific clinical course of young patients with Brugada syndrome
- 5 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (13) , 1263-1266
Sex-specific clinical course of young patients with Brugada syndrome
- Open Access
- 7 May 2024
- Published by Elsevier in JACC: Case Reports
- Vol. 29 (11) , 102364
Novel Compound Heterozygous Variants in Trans-2,3-Enoyl-Coenzyme A Reductase-Like Gene Associated With Catecholaminergic Polymorphic Ventricular Tachycardia
- 7 May 2024
- Published by Elsevier in JACC: Case Reports
- Vol. 29 (11) , 102364
Open AccessNovel Compound Heterozygous Variants in Trans-2,3-Enoyl-Coenzyme A Reductase-Like Gene Associated With Catecholaminergic Polymorphic Ventricular Tachycardia
- Open Access
- 27 November 2023
- Published by Wiley in Journal of Arrhythmia
- Vol. 40 (1) , 17-25
Expert consensus document on automated diagnosis of the electrocardiogram: The task force on automated diagnosis of the electrocardiogram in Japan part 3: Inappropriate internal processing in the automatic diagnosis of electrocardiograms and its problems
Computer diagnosis of electrocardiograms is widely used to provide useful information in clinical practice and medical checkups. However, it is common for users to be confused by the inappropriate diagnosis. We illustrate some examples of inappropriate automatic diagnoses and discuss the actual situation of inappropriate automatic processing and its problems.
- 27 November 2023
- Published by Wiley in Journal of Arrhythmia
- Vol. 40 (1) , 17-25
Open AccessExpert consensus document on automated diagnosis of the electrocardiogram: The task force on automated diagnosis of the electrocardiogram in Japan part 3: Inappropriate internal processing in the automatic diagnosis of electrocardiograms and its problems
Computer diagnosis of electrocardiograms is widely used to provide useful information in clinical practice and medical checkups. However, it is common for users to be confused by the inappropriate diagnosis. We illustrate some examples of inappropriate automatic diagnoses and discuss the actual situation of inappropriate automatic processing and its problems.
- Open Access
- 1 March 2023
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 16 (3) , e011497
Novel Ablation Strategy Targeting the Slow Pathway Visualized by Ultrahigh-Resolution Mapping in Typical Slow-Fast Atrioventricular Nodal Reentrant Tachycardia
- 1 March 2023
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 16 (3) , e011497
Open AccessNovel Ablation Strategy Targeting the Slow Pathway Visualized by Ultrahigh-Resolution Mapping in Typical Slow-Fast Atrioventricular Nodal Reentrant Tachycardia
- Open Access
- 9 January 2023
- Published by Springer Nature in Heart and Vessels
- Vol. 38 (9) , 1191
Author’s reply: Efficacy of a phosphodiesterase type 5 inhibitor on the pulmonary artery index and postoperative hemodynamics after a Fontan operation
- 9 January 2023
- Published by Springer Nature in Heart and Vessels
- Vol. 38 (9) , 1191
Open AccessAuthor’s reply: Efficacy of a phosphodiesterase type 5 inhibitor on the pulmonary artery index and postoperative hemodynamics after a Fontan operation
- 30 November 2022
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 9 (2) , 283-296
Response to Para-Hisian Pacing in the Setting of Presence of a Concealed Nodoventricular/Nodofascicular Pathway
- 30 November 2022
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 9 (2) , 283-296
Response to Para-Hisian Pacing in the Setting of Presence of a Concealed Nodoventricular/Nodofascicular Pathway